37 results about "Mouse Leukemia" patented technology

The invention discloses a method and a special culture medium for subculturing chicken embryonic stem cells for a long time. The method is characterized by comprising the following steps of: isolating cells of area pellucida of X-stage blastoderm, dispersing into single cells or small cell masses through mechanical blowing and beating, inoculating on an STO feeder layer, culturing the chicken embryonic stem cells in the special culture medium at the temperature of between 37 and 38 DEG C, and subculturing once every 3 to 5 days, wherein the special culture medium comprises 600 to 900mL of conditioned medium, 50 to 150mL of fetal calf serum, 5 to 20mL of chicken serum, 5 to 25mL of one or a mixture of more of non-essential amino acids, 0.146 to 0.292g of L-glutamine, 6 to 14mu L of beta-mercaptoethanol, 1 to 2*10<6> IU of mouse leukemia inhibitory factor, 10 to 50mu g of alkaline fibroblastic growth factor and 5 to 20mu g of stem cell growth factor; and fixing the volume of the ingredients to 1,000mL by using a dulbecco's modified eagle medium (DMEM) (high glucose), and regulating the pH value to 7.2 to 7.5. The conditioned medium is obtained by the steps of: culturing BRL-3A cells until the cells are converged, collecting supernatant of the cultured cells, performing centrifugal separation, and filtering by using a filter membrane to obtain the conditioned medium. Compared with the prior art, the method has the advantages that: the long-term subculture of the chicken embryonic stem cells can be realized, the proliferation of the cells is quick, and the cloning yield is high.

The invention relates to a long-chain non-coding RNA IncRNA-BcrAR and application thereof in cell canceration resistance. IncRNA-BcrAR is in low-level expression in a human chronic myelogenous leukemia cell line K562 with positive Bcr-Abl, the K562 cell line with overexpressed IncRNA-BcrAR is constructed, the action of IncRNA-BcrAR on Bcr-Abl induced cell neoplastic transformation is observed, experiments prove that the IncRNA-BcrAR overexpression can obviously promote K562 cell apoptosis induced by Imatinib (therapeutic drug of Abl positive leukemia patients) and can remarkably inhibit tumor growth induced by K562 cells in a naked mouse body; and besides, the IncRNA-BcrAR overexpression can remarkably promote A-MuLV transformed mouse leukemia cell BC44 apoptosis induced by Imatinib. The IncRNA-BcrAR has important effect on Bcr-Abl and v-Abl mediated cell canceration resistance, and the long-chain non-coding RNA IncRNA-BcrAR provides new molecular marker and drug target for diagnosis and treatment of Abl induced leukemia.

The invention discloses an application of long-chain non-coding RNA LAMP5-AS1 to MLL-R leukemia. Specifically, LAMP5-AS1 in a patient suffering from MLL fusion gene leukemia is notably and highly expressed, and besides, highly expressed LAMP5-AS1 presents notable negative correlation with the survival rate of the patient. The result of a mouse leukemia model indicates that through knocking down ofthe expression of the LAMP5-AS1, survival of MLL fusion gene leukemia can be notably restrained, and the life cycle of the model mouse can be notably prolonged. The experiment indicates that the LAMP5-AS1 can be used as a diagnosis marker and/or a treatment target point to exert effects in MLL-R leukemia.

The invention relates to novel beta-chloroethylnitrosourea compounds, and a synthesis method and application thereof. The structure of the beta-chloroethylnitrosourea compounds is disclosed as general formula (II). The in-vitro antitumor screening test on the compounds disclosed as general formula II proves that the compounds disclosed as general formula I have obvious inhibiting action on human cerebral nerve glioma cells SF763, SF767, SF126 and SF188, human colon cancer cell HT29, mouse leukaemia cell L1210 and many other tumor cell lines and have higher tumor inhibiting activity than the existing CENU and CENU/O6-benzylguanine combined medicine.

The invention provides a preparation method of a bone-knitting tablet. The bone-knitting tablet is prepared by using 39g of szechuan lovage rhizome, 39g of radix aconiti preparata, 39g of Chinese angelica, 39g of frankincense stir-fried with vinegar, 39g of myrrh stir-fried with vinegar and 39g of forged natural coppers as bulk drugs and adopting supercritical extraction and microwave-assisted extraction modes. By adopting the method, the content of ferulic acid is greatly improved; and the invention also provides application of the bone-knitting tablet in preparation of drugs for inhibiting cell proliferation of mice leukemia cell NFS-60.

The invention provides a preparing method of bone setting zijin pills. Cloves of 50g, lotus nuts of 100g, cooked rhubarb of 50g, catechu of 50g, stir-baked white paeony roots of 100g, sanguis draconis of 50g, moutan bark of 25g, Chinese angelica of 100g, elecampane of 50g, poria cocos of 100g, flos carthami of 50g and liquorice of 15g are used as raw materials to prepare the bone setting zijin pills. The bone setting zijin pills are formed through supercritical extraction, so that the content is greatly improved, and the dose is lowered. The invention further provides an application of the bone setting zijin pills in preparing medicine for inhibiting mice leukemia L1210 cell proliferation.

The invention relates to an application of a mouse leukemia cell L1210 in the preparation of an HIV-1 infectible host cell, and also relates to the HIV-1 infectible host cell. The mouse leukemia cell L1210 is a mouse leukemia cell L1210 with CD4 and CCR5 expressed on the surface of the cell and Cyclin T1 expressed in the cell. The invention also relates to a preparation method of the HIV-1 infectible host cell, and an application of the HIV-1 infectible host cell. The HIV-1 infectible host cell obtained in the invention can be highly-efficiently infected by HIV-1, virus particles replicated in the infected cell has infection activity, and the infected cell secretes active HIV-1 virus to the outside of the cell. The HIV-1 infectible host cell can be used for treating and researching HIV-1 infection and developing anti-HIV-1 drugs.

The invention relates to the field of medicines, in particular to a use of XRK3F2 in the preparation of a medicine for treating leukemia. The p62 small-molecule inhibitor XRK3F2 disclosed by the invention has good inhibition effects on MLL-AF9 AML mouse leukemia stem progenitor cells and human leukemia stem progenitor cells, and a new method can be provided for future clinical treatment.

The invention provides application of an anti-pharyngitis tablet in preparing a drug for inhibiting L1210 mice leukemia cell proliferation. The preparation method of the anti-pharyngitis tablet comprises the following steps: taking 120 g radix scrophulariae, 90 g radix stemonae, 90 g asparagus fern, 90 g moutan bark, 90 g radix ophiopogonis, 90 g flos farfarae, 30 g oroxylum indicum, 90 g rhizoma rehmanniae, 150 g radix isatidis, 90 g Chinese olive, 30 g cicada slough and 0.3 g mint oil, except the mint oil, crushing the flos farfarae into fine powder, screening the fine powder; decocting the other ten materials with water twice, combining the decoctions, standing the mixed liquor for 24 hours, taking the supernatant to concentrate to be a thick paste, mixing the thick paste with the flos farfarae fine powder, drying the mixture, turning out particles, spraying the mint oil on the particles, mixing uniformly, tabletting the mixed particles into 1000 tablets, and coating sugar coat on the tablets to obtain the finished product.

The invention relates to the technical field of medicines, in particular to 7 novel dimerization and trimerization aaptamine alkaloid compounds having antineoplastic activity. The 7 novel dimerization and trimerization aaptamine alkaloid compounds are separated from sponge Aaptos suberitoides (1934) collected in the South Sea of China. Vitro antineoplastic activity experiments show that the alkaloid compounds has evident inhibition effect to tumor cells such as K562 (chronic myelocytic leukemia) and P388 (mouse leukemia cells) and can be used to prepare antineoplastic drugs. By the alkaloid compounds, lead compounds for researching novel antineoplastic drugs are provided, and development and utilization of marine medicinal resources are facilitated.

The invention relates to a novel amino/acyl substituted β-carboline compound, a preparation method and application of antitumor activity. The invention transforms the structure of the gamma-carboline mother core to obtain the beta-carboline derivatives with basic side chain substitution. The compound of the present invention shows good antitumor activity through pharmacodynamic HL60 human leukemia and P388 mouse leukemia cell line antitumor activity tests, and can prepare novel antitumor drugs.

The invention discloses a syngnathus acus antineoplastic active protein in the medicine technology field, which is an active protein whose molecular weight is 60 kDa which is extracted through using syngnathus acus as raw material. The outer appearance of protein is white powder, SDS-PAGE shows a single strip, and HPLC shows a single peak. The syngnathus acus antineoplastic active protein which is provided by the invention has the characteristics of antineoplastic activity and low toxicity. The invention has the antineoplastic activity by being used individually or used through combining with other pharmacophysics, which is mainly used for the therapy or auxiliary therapy of various cancers, such as lung cancer, liver cancer, cervical cancer, colon cancer, and leukemia and the like, and has specially stronger habitation effect for LOVO human colon cancer cell line, A5489 (human lung cancer cell line), L1210 (mouse leukemia cell line) and CCRF-CEM (human leukemia cell line).

The invention discloses an application of a protein serine integration factor 2 in MLL fusion gene leukemia. A large number of leukemia patient samples are detected through real-time quantitative PCR, and it is found that SERINC2 in MLL fusion gene leukemia patients is remarkably high in expression; and then the expression of SERINC2 is knocked down, so that the survival of MLLR leukemia cells can be remarkably inhibited; meanwhile, the result of a mouse leukemia model shows that the life cycle of a model mouse can be remarkably prolonged by knocking down the expression of the SERINC2, and the SERINC2 can be used as a diagnosis marker and/or a treatment target to play a role in MLLR leukemia. Therefore, the invention can provide a new accurate treatment strategy and genetic resource for targeted treatment of MLL fusion gene leukemia, and has important theoretical significance and application value.

The invention discloses application of a heat-clearing and stasis-removing tablet in preparation of a drug for preventing and treating leukemia. Different human leukemia cell strains HEL, K562, Daudi and Jurkat and a mouse leukemia cell strain CB3 are applied in vitro for detection, it is found that the heat-clearing and stasis-removing tablet has a remarkable effect of inhibiting leukemia cell proliferation. The median inhibitory concentration IC50 values of the strains in 72h are as follows: CB3: 0.134 +/-0.012 mg/mL; Jurkat: 0.792+/-0.296mg/mL; Daudi: 0.775+/-0.052mg/mL; HEL: 1.027+/-0.625mg/mL; K562: 1.756+/-0.406mg/mL; and 7702: 7.153+/-1.073mg/mL. Meanwhile, a plurality of signal paths such as PI3K-AKT, MAPK, mTOR and NF-kappa B can be blocked to induce apoptosis of human acute lymphocytic leukemia cells Jurkat; and the heat-clearing and stasis-removing tablet can be used as a preparation for preventing and treating leukemia to be prepared into pharmaceutically allowable oral liquid, injection, tablets, capsules, dripping pills and the like.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a preparation method and application of a liver benefiting tablet containing nepal dock root and day lily. The liver benefiting tablet is prepared by using 291g of nepal dock root, 103g of day lily, 92g of herb of raywort, 92g of yangtao, 92g of Smilax ocreafa A. DC, 62g of wild rose, 62g of swertia, 62g of pimoinella candolleana, and 62g of southern schisandra fruit as raw material, and adopting supercritical extraction, microwave extraction and macroporous resin absorption, so that the condition that the content of emodin is greatly improved is ensured. The invention also provides the application of the liver benefiting tablet to preparation of drug for restraining multiplication of a mouse leukemia cell L1210 cell.

The invention provides a monoclonal antibody specifically binding to human CD47 or a fragment thereof, which can bind to CD47 on the surface of a cell and block binding of SIRP alpha to CD47 on the surface of the cell. The affinity KD value on the recombinant human CD47 is between 1 * 10 <-10 > and 8 * 10 <-8 >, and the tumor inhibition activity and the adverse reaction activity can be balanced. In the aspect of tumor inhibition activity, the antibody can inhibit tumor growth in a CD47/SIRP alpha double-transgenic mouse tumor-bearing hCD47-MC38 subcutaneous transplanted tumor model, and can enhance in-vivo cell phagocytosis and prolong the lifetime of a mouse in a mouse leukemia model of transplanted human acute B lymphocytic leukemia; in the aspect of adverse reaction activity, the antibody does not have or only has reduced erythrocyte agglutination activity, and does not have a significant effect or only has an over-sexual effect on erythrocytes, platelets and hemoglobin.

The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a preparation method of a fomitopsis officinalis tablet capable of treating cough and asthma and application of the tablet. The fomitopsis officinalis tablet capable of treating cough and asthma is prepared from 20 g of fomitopsis officinalis, 100 g of plum, 80 g of reed rhizome, 60 g of licorice, 50 g of ephedra, 30 g of elecampane, 120 g of aniseed, 30 g of rhizoma cyperi, and 20 g of cardamom as raw materials, and prepared by supercritical extraction and microwave-assisted extraction, so as to greatly increase the content of glycyrrhizic acid. The invention further provides application of the fomitopsis officinalis tablet capable of treating cough and asthma in preparing a drug for inhibiting cell proliferation of mouse leukemia cell L6565.